TG Therapeutics Raises 2026 Revenue Guidance to $1 Billion Amid BRIUMVI Growth
TG Therapeutics (TGTX) has announced an upward revision of its full-year global revenue guidance for 2026, now targeting the $1 billion milestone. This optimism follows a strong third quarter where global revenue reached approximately $260 million, driven largely by $233 million in net revenue from BRIUMVI in the United States. The company is focusing on long-term market expansion through product lifecycle management. Key upcoming milestones include plans to introduce a simplified intravenous (IV) dosing regimen in mid-2027, followed by the launch of a subcutaneous (subcu) formulation in 2028 to further enhance patient convenience and market penetration.
Tickers: $TGTX
Topics: biotechnology BRIUMVI sales earnings report revenue guidance
Read the full article at Seeking Alpha
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)